500 patients to be tracked for long-term safety of cancer cell therapy
NCT ID NCT06785818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 500 people in South Korea who have received tisagenlecleucel, a CAR-T cell therapy, for certain blood cancers like acute lymphoblastic leukemia and lymphomas. Researchers will monitor side effects, risk of new cancers, and how well the treatment works over time. The goal is to understand the therapy's long-term safety in routine medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGBundang Gu, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
RECRUITINGSeongnam-si, Gyeonggi-do, 463-712, South Korea
-
Novartis Investigative Site
RECRUITINGGyeonggi-do, Korea, 10408, South Korea
-
Novartis Investigative Site
RECRUITINGIncheon, Korea, 405 760, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 02841, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Korea, 08308, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 150-713, South Korea
-
Novartis Investigative Site
RECRUITINGBusan, 49201, South Korea
-
Novartis Investigative Site
RECRUITINGJeollanam, 519763, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03722, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 04401, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGUlsan, 44033, South Korea